Laboratory evaluation of CHG containing IV dressings

  • Research type

    Research Study

  • Full title

    A laboratory evaluation of 3M™ Tegaderm™ CHG IV Securement Dressing in comparison with Biopatch® dressing

  • IRAS ID

    192643

  • Contact name

    TSJ Elliott (RETIRED)

  • Contact email

    Tom.Elliott@uhb.nhs.uk

  • Sponsor organisation

    University Hospital Birmingham NHS Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    In this laboratory study, we wish to investigate intravascular catheter (IV) dressings (dressings applied on the skin over a tube going into a patient's blood stream) which contain an antiseptic called chlorhexidine (CHG). During this study, it may be possible to demonstrate that one of the dressings releases higher amount of CHG onto the skin surface, allowing greater penetration of CHG into the skin, and reducing skin colonisation with harmful bacteria that may cause infection in patients who have IV catheters. This may be beneficial in the future to patients who require these medical devices.

    We wish to evaluate the antimicrobial efficacy of the 3M™ Tegaderm chlorhexidine IV dressing in comparison with a Biopatch® dressing using a human skin model in the laboratory. The skin model enables evaluation of the antimicrobial efficacy of the dressings against pathogenic microorganisms in an environment similar to normal human skin. These microorganisms include methicillin­-resistant Staphylococcus aureus (MRSA), which commonly causes infections in patients with IV catheters. Furthermore, it enables us to investigate the quantity and depth of CHG penetration into the various layers of skin.

    The laboratory experiments include time-­kill assays (rate of killing of microorganisms), with the dressings alone or with a segment of IV catheter. Chlorhexidine diffusion from the dressings onto the skin and retention within the various layers of skin will also be evaluated.

    The study is funded by 3M Health Care, USA. The study will be undertaken in the microbiology laboratories at the University Hospitals Birmingham NHS Foundation Trust and Aston University, in collaboration with a pharmacology expert at the University of Huddersfield, over a 12­-month period. Anonymised human donor skin obtained from a HTA licensed tissue services will be used for this research.

  • REC name

    West of Scotland REC 5

  • REC reference

    15/WS/0275

  • Date of REC Opinion

    19 Nov 2015

  • REC opinion

    Favourable Opinion